Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioconjug Chem ; 27(9): 2062-70, 2016 09 21.
Artigo em Inglês | MEDLINE | ID: mdl-27506475

RESUMO

Fluoroquinolones are third-generation broad spectrum bactericidal antibiotics and work against both Gram-positive and Gram-negative bacteria. Levofloxacin (L), a fluoroquinolone, is widely used in anti-infective chemotherapy and treatment of urinary tract infection and pneumonia. The main pathogen for urinary tract infections is Escherichia coli, and Streptococcus pneumoniae is responsible for pneumonia, predominantly a lower respiratory tract infection. Poor permeability of L leads to the use of higher dose of this drug and excess drug in the outer cellular fluid leads to central nervous system (CNS) abnormality. One way to counter this is to improve the lipophilicity of the drug molecule, and accordingly, we have synthesized two new Levofloxacin derivatives, which participated in the spatiotemporal release of drug via disulfide bond cleavage induced by glutathione (GSH). Recent studies with Streptococcus mutants suggest that it is localized in epithelial lining fluid (ELF) of the normal lower respiratory tract and the effective [GSH] in ELF is ∼430 µM. E. coli typically cause urinary tract infections and the concentration of GSH in porcine bladder epithelium is reported as 0.6 mM for a healthy human. Thus, for the present study we have chosen two important bacteria (Gram + ve and Gram - ve), which are operational in regions having high extracellular GSH concentration. Interestingly, this supports our design of new lipophilic Levofloxacin based prodrugs, which released effective drug on reaction with GSH. Higher lipophilicity favored improved uptake of the prodrugs. Site specific release of the drug (L) could be achieved following a glutathione mediated biochemical transformation process through cleavage of a disulfide bond of these purpose-built prodrugs. Further, appropriate design helped us to demonstrate that it is possible also to control the kinetics of the drug release from respective prodrugs. Associated luminescence enhancement helps in probing the release of the drug from the prodrug in bacteria and helps in elucidating the mechanistic pathway of the transformation. Such an example is scarce in the contemporary literature.


Assuntos
Liberação Controlada de Fármacos , Escherichia coli/metabolismo , Glutationa/metabolismo , Levofloxacino/química , Levofloxacino/metabolismo , Pró-Fármacos/metabolismo , Staphylococcus aureus/metabolismo , Antibacterianos/química , Antibacterianos/metabolismo , Antibacterianos/farmacologia , Preparações de Ação Retardada , Escherichia coli/efeitos dos fármacos , Levofloxacino/farmacologia , Medições Luminescentes , Staphylococcus aureus/efeitos dos fármacos
2.
Chem Commun (Camb) ; 52(36): 6166-9, 2016 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-27075169

RESUMO

We report a new chemodosimetric reagent capable of detecting hydrazine in the presence of several other competing amine derivatives and ionic analytes of biological relevance. This reagent has been utilized for real time monitoring of in situ N2H4 release during the metabolism of a crucial tuberculosis drug, isoniazid, in live HepG2 cells. The fluorescence response of the reagent based on its specific reaction with N2H4 is used for developing an in vitro assay for aminoacylase-1.


Assuntos
Amidoidrolases/metabolismo , Ensaios Enzimáticos , Hidrazinas/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Células HCT116 , Células Hep G2 , Humanos , Hidrazinas/química , Isoniazida/química , Isoniazida/metabolismo , Isoniazida/toxicidade , Medições Luminescentes , Microscopia Confocal , Dióxido de Silício/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...